Taken together, these data seem to suggest that sAxl levels are an early marker of NASH that correlates with disease development and, at least in experimental NASH models, that therapeutic inhibition of Axl can diminish liver fibrosis by blocking HSC activation and reducing hepatic inflammation, possibly due to Gas6 hepatoprotective action [99]. Here, AXL is linked to Hepatic fibrosis.